Shift in Sales Timing and Impact on Business Performance Due to COVID-19
First written in FY2020. 7 of 15 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2024SoftenedAnnual report
「The Japanese economy during the current consolidated fiscal year showed signs of a gradual recovery as the transition of COVID-19 to Category V under the Infectious Diseases Control Law led to further progress toward the normalization of social and economic activities.」
The description of COVID-19 has shifted from continued references to the expected end of the pandemic, accounting assumptions and ongoing operating restrictions to references indicating the transition to Category 5 and the normalization of social and economic activity. - FY2024-Q3RestatedAnnual report
「The company assumes that COVID-19 will be brought under control during the fiscal year ending January 2024, in light of the normalization of social activities, including the decision in Japan to move the infection's legal classification to Category V, and that economic conditions will improve in the fiscal year ending January 2025. It has made accounting estimates, including impairment of fixed assets, on that basis. There have been no material changes to the assumptions and accounting estimates described in the securities report for the previous consolidated fiscal year concerning the effects of the spread of COVID-19 and other factors. However, as the impact of COVID-19 remains highly uncertain, any changes in the above assumptions may affect the Group's future business performance and financial position.」
The company has continued to use the accounting assumptions that the infection will be brought under control during the fiscal year ending January 2024 and that economic conditions will improve in the fiscal year ending January 2025, with no material changes from the previous consolidated fiscal year. - FY2024-Q2RestatedAnnual report
「The company assumes that COVID-19 will be brought under control during the fiscal year ending January 2024, in light of the normalization of social activities, including the decision in Japan to move the infection's legal classification to Category V, and that economic conditions will improve in the fiscal year ending January 2025. It has made accounting estimates, including impairment of fixed assets, on that basis. There have been no material changes to the assumptions and accounting estimates described in the securities report for the previous consolidated fiscal year concerning the effects of the spread of COVID-19 and other factors.」
The company has continued to use the accounting assumptions that the infection will be brought under control during the fiscal year ending January 2024 and that economic conditions will improve in the fiscal year ending January 2025, with no material changes from the previous consolidated fiscal year. - FY2024-Q1RestatedAnnual report
「The company assumes that COVID-19 will be brought under control during the fiscal year ending January 2024, in light of the normalization of social activities, including the decision in Japan to move the infection's legal classification to Category V, and that economic conditions will improve in the fiscal year ending January 2025. It has made accounting estimates, including impairment of fixed assets, on that basis. There have been no material changes to the assumptions and accounting estimates described in the securities report for the previous consolidated fiscal year concerning the effects of the spread of COVID-19 and other factors.」
The company has continued to assume that the infection will be brought under control during the fiscal year ending January 2024 and that economic conditions will improve in the fiscal year ending January 2025, with no material changes from the previous consolidated fiscal year. - FY2023WorsenedAnnual report
「The company assumes that COVID-19 will be brought under control during the fiscal year ending January 2024, in light of the normalization of social activities, including the decision in Japan to move the infection's legal classification to Category V, and that economic conditions will improve in the fiscal year ending January 2025. It has made accounting estimates, including impairment of fixed assets, on that basis.」
The assumed timing for the infection to be brought under control was pushed back from the fiscal year ending January 2023 to the fiscal year ending January 2024, and the assumed timing for economic improvement was pushed back from the fiscal year ending January 2024 to the fiscal year ending January 2025. - FY2023-Q3RestatedAnnual report
「There have been no material changes to the assumptions and accounting estimates described in the securities report for the previous consolidated fiscal year concerning the effects of the spread of COVID-19 and other factors. However, as the impact of COVID-19 remains highly uncertain, any changes in the above assumptions may affect the Group's future business performance and financial position.」
There have been no material changes to the accounting assumptions and estimates concerning the effects of the infection, while the uncertainty surrounding its impact continues to be disclosed. - FY2023-Q2WorsenedAnnual report
「In addition, the number of COVID-19 cases rose sharply from July onward and the seventh wave arrived, requiring attention to a further downside in economic conditions. ... As the impact of COVID-19 remains highly uncertain, any changes in the above assumptions may affect the Group's future business performance and financial position.」
The company newly stated that the sharp increase in infections and the resulting seventh wave require attention to a further downside in economic conditions. Meanwhile, there have been no material changes to the accounting assumptions that the infection will be brought under control during the fiscal year ending January 2023 and that economic conditions will improve in the fiscal year ending January 2024. - FY2023-Q1RestatedAnnual report
「The company's business activities have been affected by stagnation of sales activities due to domestic and international travel restrictions and delays in customers' capital investment caused by COVID-19. The company assumes that the infection will be brought under control during the fiscal year ending January 2023 and that economic conditions will begin to improve in the fiscal year ending January 2024, and has made accounting estimates, including impairment of fixed assets, on that basis.」
Although stagnation of sales activities and delays in capital investment have continued, there have been no material changes to the assumptions that the infection will be brought under control during the fiscal year ending January 2023 and that economic conditions will improve in the fiscal year ending January 2024. - FY2022WorsenedAnnual report
「The company assumes that COVID-19 will be brought under control during the fiscal year ending January 2023 and that economic conditions will begin to improve in the fiscal year ending January 2024, and has made accounting estimates, including impairment of fixed assets, on that basis.」
The assumed timing for the infection to be brought under control was pushed back from the fiscal year ending January 2022 to the fiscal year ending January 2023, and the assumed timing for economic improvement was pushed back from the fiscal year ending January 2023 to the fiscal year ending January 2024. - FY2022-Q3RestatedAnnual report
「The company's business activities have been affected by stagnation of sales activities due to domestic and international travel restrictions and delays in customers' capital investment caused by COVID-19. The company assumes that the infection will be brought under control during the fiscal year ending January 2022 and that economic conditions will begin to improve in the fiscal year ending January 2023, and has made accounting estimates, including impairment of fixed assets, on that basis.」
Although stagnation of sales activities and delays in capital investment have continued, there have been no material changes to the assumptions that the infection will be brought under control during the fiscal year ending January 2022 and that economic conditions will improve in the fiscal year ending January 2023. - FY2022-Q2RestatedAnnual report
「The company's business activities have been affected by stagnation of sales activities due to domestic and international travel restrictions and delays in customers' capital investment caused by COVID-19. The company assumes that the infection will be brought under control during the fiscal year ending January 2022 and that economic conditions will begin to improve in the fiscal year ending January 2023, and has made accounting estimates, including impairment of fixed assets, on that basis.」
Although stagnation of sales activities and delays in capital investment have continued, there have been no material changes to the assumptions that the infection will be brought under control during the fiscal year ending January 2022 and that economic conditions will improve in the fiscal year ending January 2023. - FY2022-Q1WorsenedAnnual report
「The company's business activities have been affected by stagnation of sales activities due to domestic and international travel restrictions and delays in customers' capital investment caused by COVID-19. The company assumes that the infection will be brought under control during the fiscal year ending January 2022 and that economic conditions will begin to improve in the fiscal year ending January 2023, and has made accounting estimates, including impairment of fixed assets, on that basis.」
Stagnation of sales activities and delays in capital investment caused by the infection have continued. The assumed timing for the infection to be brought under control has been extended to the fiscal year ending January 2022, and the assumed timing for economic improvement to the fiscal year ending January 2023. - FY2021-Q2WorsenedAnnual report
「The company's business activities have been affected by stagnation of sales activities due to domestic and international travel restrictions and delays in customers' capital investment caused by COVID-19. The company assumes that the infection will be brought under control during the fiscal year ending January 2021 and that economic conditions will begin to improve in the fiscal year ending January 2022, and has made accounting estimates, including impairment of fixed assets, on that basis. JPN,INC., a consolidated subsidiary, was significantly affected in its business activities, including operating restrictions in the Philippines due to the spread of COVID-19, from the second quarter of the current consolidated fiscal year. As a result, its net sales and profit declined from the same period of the previous year.」
The effects of the infection emerged as stagnation of sales activities, delays in capital investment and lower net sales and profit at JPN,INC. due to operating restrictions in the Philippines. Accounting estimates were made assuming that the infection would be brought under control during the fiscal year ending January 2021 and that the economy would improve in the fiscal year ending January 2022. - FY2021-Q1WorsenedAnnual report
「The Group's business activities were also affected, including the temporary suspension of operations at overseas subsidiaries and stagnation of sales activities due to domestic and international travel restrictions.」
The effects of COVID-19 expanded beyond the previous sales timing delays and business performance impact to include temporary suspension of operations at overseas subsidiaries, domestic and international travel restrictions, and stagnation of sales activities. - FY2020MaterialisedAnnual report
「The Group's business performance was also affected by COVID-19 during the current consolidated fiscal year. If the outbreak of the infection expands further, it may continue to affect the Group's financial position, business performance and other matters.」
The company stated that COVID-19 actually affected business performance during the current consolidated fiscal year and that sales of inkjet coaters were also delayed.